Iron overload in myelodysplastic syndromes (MDS)
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2017/11/25
-
Indian UGC (journal)
-
Refrences63
-
Citations65
-
Norbert Gattermann
Cite
Gattermann, Norbert. “Iron Overload in Myelodysplastic Syndromes (MDS)”. International Journal of Hematology, vol. 107, no. 1, 2017, pp. 55-63, https://doi.org/10.1007/s12185-017-2367-1.
Gattermann, N. (2017). Iron overload in myelodysplastic syndromes (MDS). International Journal of Hematology, 107(1), 55-63. https://doi.org/10.1007/s12185-017-2367-1
Gattermann N. Iron overload in myelodysplastic syndromes (MDS). International Journal of Hematology. 2017;107(1):55-63.
Journal Categories
Medicine
Internal medicine
Specialties of internal medicine
Diseases of the blood and blood-forming organs
Medicine
Medicine (General)
You May Also Like
- Mechanism of thrombocytopenia in COVID-19 patients
- Epidemiology of non-Hodgkin?s lymphoma (NHL): trends, geographic distribution, and etiology
- The IgG Fc receptor family
- Renal failure in multiple myeloma: reversibility and impact on the prognosis
- Erythropoietin after a century of research: younger than ever
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| 10.1182/blood.V128.22.1285.1285 | 2016 | |||
| 10.1182/blood.V128.22.850.850 | 2016 | |||
| 10.1182/blood.V126.23.2842.2842 | 2015 | |||
| Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications | Annals of Hematology |
| 45 | 2015 |
| Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome – Emphasis on optimized dosing schedules and new formulations | Leukemia Research |
| 10 | 2015 |
Refrences Analysis
The category
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs 63
is the most frequently represented among the references in this article. It primarily includes studies from Leukemia Research The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
The clinical characteristics, gene mutations and outcomes of myelodysplastic syndromes with diabetes mellitus | Journal of Cancer Research and Clinical Oncology |
| 2024 | |
| Synthesis of iron-boride/carbon-nitride composites and their applications in chemodynamic therapy | Journal of Colloid and Interface Science |
| 2024 | |
| Salubrinal promotes phospho-eIF2α-dependent activation of UPR leading to autophagy-mediated attenuation of iron-induced insulin resistance | Molecular Metabolism |
| 2024 | |
The Role of Hepcidin in Myelodysplastic Syndromes (MDS): A Systematic Review of Observational Studies | Cancers |
| 1 | 2024 |
Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine—A Retrospective Analysis | Cancers |
| 2024 |
Citations Analysis
The category
Medicine: Medicine (General) 42
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Iron overload cardiomyopathy and was published in 2018. The most recent citation comes from a 2024 study titled Deregulation of New Cell Death Mechanisms in Leukemia. This article reached its peak citation in 2021, with 18 citations. It has been cited in 46 different journals, 26% of which are open access. Among related journals, the Cancers cited this research the most, with 3 citations. The chart below illustrates the annual citation trends for this article.